nivolumab

Open Access
The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab
ONDREJ FIALA, MICHAELA TKADLECOVA, JINDRICH KOPECKY, PETR HOSEK, HANA STUDENTOVA, MICHAL VOCKA, MARTIN MATEJU, RADKA LOHYNSKA, DOMINIKA SIKOVA, PETR STRANSKY, RADEK KUCERA, ANEZKA ZEMANKOVA, MARTINA SPISAROVA, PETER PRIESTER, JAN KOURIL, TOMAS BUCHLER, LUCIE GRMELOVA, BOHUSLAV MELICHAR and ALEXANDR POPRACH

In Vivo March 2026, 40 (2) 1065-1079; DOI: https://doi.org/10.21873/invivo.14261
Open Access
Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and Neck Cancer
YOH-ICHIRO IWASA, RYOSUKE KITOH, YOH YOKOTA, KENTARO HORI, MARIKO KASUGA, SHINTARO YAMAZAKI and YUTAKA TAKUMI

In Vivo September 2025, 39 (5) 2777-2786; DOI: https://doi.org/10.21873/invivo.14076
Open Access
Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma
THIBAUD LOUPRET, ROMAIN BOISSEAU, JEAN-GUILLAUME LOPEZ, PHILIPPE BERTIN and PASCALE VERGNE-SALLE

In Vivo May 2024, 38 (3) 1451-1453; DOI: https://doi.org/10.21873/invivo.13589
Open Access
Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab
YURI HIRAI, KEI KURIHARA, DAISUKE SANO, MANA INAMO, HIDEAKI TAKAHASHI, YASUSHI ICHIKAWA and NOBUHIKO ORIDATE

In Vivo November 2023, 37 (6) 2687-2695; DOI: https://doi.org/10.21873/invivo.13378
Open Access
Humanized PD-1 Knock-in Mice Reveal Nivolumab’s Inhibitory Effects on Glioblastoma Tumor Progression In Vivo
CHUN-YU CHIANG, MENG-CHU HUANG, SHIH-CHONG TSAI, FEI-TING HSU, TSAI-LAN LIAO, JEI-HWA YU, TZU-HSIANG LIN, HUA-HSIH HUANG and PEN-AN LIAO

In Vivo September 2023, 37 (5) 1991-2000; DOI: https://doi.org/10.21873/invivo.13296
Open Access
Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
JIRI BLAZEK, PETR HOSEK, KAROLINA HRABCOVA, MONIKA BRATOVA, JURAJ KULTAN, MICHAL HRNCIARIK, MARKETA CERNOVSKA, PETRA ZEMANOVA, JANA KREJCI, LEONA KOUBKOVA, MAREK STASTNY and MARTIN SVATON

In Vivo September 2023, 37 (5) 2229-2236; DOI: https://doi.org/10.21873/invivo.13324
Open Access
Adverse Events in Patients With Esophageal Cancer Treated With Nivolumab in Combination With Radiotherapy
YASUSHI RINO, TORU AOYAMA, YUKIO MAEZAWA, KAZUKI KANO, MIHWA JU, HIROSHI TAMAGAWA, SHO SAWAZAKI, KEISUKE KAZAMA, HARUKA KANAI, TSUTOMU SATO, AYA SAITO and NORIO YUKAWA

In Vivo July 2023, 37 (4) 1760-1764; DOI: https://doi.org/10.21873/invivo.13264
Open Access
Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
TOMOMI MANAKO, RYUJI YASUMATSU, TAKAFUMI NAKANO, MIOKO MATSUO, TORANOSHIN TAKEUCHI, MASAHIKO TAURA, AKIHIRO TAMAE, MORIYASU YAMAUCHI, MUNEYUKI MASUDA, KENICHI TAGUCHI and TAKASHI NAKAGAWA

In Vivo March 2023, 37 (2) 747-755; DOI: https://doi.org/10.21873/invivo.13137
Open Access
Albumin–derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study
NOBUHIRO NAKAZAWA, MAKOTO SOHDA, KOHEI TATENO, TAKAYOSHI WATANABE, AKIHARU KIMURA, NORIMICHI KOGURE, HISASHI HOSAKA, ATSUSHI NAGANUMA, MASANORI SEKIGUCHI, KANA SAITO, KYOICHI OGATA, AKIHIKO SANO, MAKOTO SAKAI, HIROOMI OGAWA, KEN SHIRABE and HIROSHI SAEKI

In Vivo March 2023, 37 (2) 818-824; DOI: https://doi.org/10.21873/invivo.13147
Open Access
Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis
YUI NEGISHI, ISAKU OKAMOTO, YURI UEDA, HIROKI SATO, MAKI TANIGAWA, TOSHITAKA NAGAO and KIYOAKI TSUKAHARA

In Vivo November 2022, 36 (6) 2840-2843; DOI: https://doi.org/10.21873/invivo.13023

Main menu

User menu

Search

nivolumab

Pages